publication date: Nov 8, 2013
More than 230,000 people—including 82 Texas state lawmakers—petitioned BioMarin Pharmaceutical Inc. to provide its investigational drug to a Austin attorney afflicted with stage IIIC ovarian cancer.
The story was getting massive coverage.
Television networks, newspapers and social media were focusing on the patient’s plight and BioMarin’s reluctance to provide the agent, BMN-673, a PARP inhibitor that stops DNA repair in cancer cells.
Several supporters got hold of the email address of the company’s CEO, Jean-Jacques Bienaimé, and contacted him directly on behalf of 45-year-old Andrea Sloan, the attorney who was trying to get the drug through compassionate use.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.